Previous Page  187 / 256 Next Page
Information
Show Menu
Previous Page 187 / 256 Next Page
Page Background

59

La autora declara no tener conflictos de interés, en relación

a este artículo.

13.

Curatolo P, Paloscia C, D’Agati E, Moavero R, Pasini A.The neurobiology of

attention deficit/hyperactivity disorder. EJPN 2009; 13: 299-304

14.

Rubia K,Alegria A, Brinson H. Imaging the ADHD brain: disorder-specificity,

medication effects and clinical translation. Expert Rev Neurother 2014; 14:

519-538.

15.

Rubia K. “Cool” inferior Frontostriatal Dysfunction in Attention-Deficit/

Hyperactivity Disorder Versus “Hot” Ventromedial Orbitofrontal-Limbic

Dysfunction in Conduct Disorder: A Review. Biol Psychiatry 2011; 69:e69-e87.

16.

Feldman H, Reiff M. Attention Deficit -Hyperactivity Disorder in Children

and Adolescents. N Engl J Med 2014; 370: 838-846

17.

Subcommittee on Attention -Deficit /Hyperactivity Disorder, Stering

Committeee on Quality Improvement and Management. ADHD: Clinical

Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention

-Deficit/Hiperactivity Disorder in Children and Adolescents. Pediatrics 2011;

128: 1007-1022

18.

Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-

5). Washington, DC: American Psychiatric Association, 2013.

19.

Mitsis E, McKay K, Schulz K, Newcorn J, Halperin J. Parent-Teacher

Concordance for DSM-IV Attention Deficit/Hyperactivity Disorder in a Clinic-

Referred Sample. J. Acad. Child Adolesc. Psychiatry 2000; 39:308-313.

20.

Wolraich M, Wibbelsman C, Brown T et al. Attention-Deficit/Hyperactivity

Disorder Among Adolescents: A review of the Diagnosis, Treatment, and

Clinical Implications. Pediatrics 2005; 115:1734-1746

21.

Pliszka S and the AACAP Work Group on Quality Issues. Practice

parameter for assessment and treatment of children and adolescents with

Attention-Deficit/Hyperactivity Disorder. J. Am. Acad. Child Adolesc. Psychiatry,

2007; 46:894-921

22.

Dunn D, Kronenberger W. Attention deficit. Handbook of Clinical

Neurology, 2013(111), Pediatric Neurology Part 1, chapter 28.

23.

Stefanatos G,Baron I.Attention/Hyperactivity Disorder:A Neuropsychological

Perspective Towards DSM-V. Neuropsychol Rev 2007; 17:5-38

24.

Sibley M, Pelham W, Molina B et al. Diagnosing ADHD in Adolescence.

Journal of Consulting and Clinical Psychology 2012; 80:139-150.

25.

Tannock R. Rethinking ADHD and LD in DSM -5: Proposed Changes in

Diagnostic Criteria. Journal of Learning Disabilities 2013; 46: 5-25

26.

Barkley R, Fisher M, Smallish L, Fletcher K.The persistence of attention deficit

hyperactivity disorder into Young adulthood as a function of reporting source

and definition disorder. Journal of Abnormal Psychology 2002: 111; 279-289

27.

Vogel W. An update on attention deficit hyperactivity disorder (ADHD). S.

Afr. Med J. 2014; 104:72-74.

28.

Obioha O, Adesman A. Pearls, perils and pitfalls in the assessment and

treatment of attention-deficit/hyperactivity disorder in adolescents. Curr Opin

Pediatr 2014; 26: 119-129

29.

Mindell J. A Clinical Guide to Pediatric Sleep: Diagnosis and Management

of sleep problems, 2nd ed. Philadelphia: Lippincott Wuilliams & Wilkins.

30.

Millichap G, Yee M. The Diet Factor in Attention -Deficit/Hyperactivity

Disorder. Pediatrics 2012;129:1-8

31.

Bloch MH, Qawasmi A. Omega -3Fatty Acid Supplementation for

the Treatment of Children with Attention Deficit/Hyperactivity Disorder

Symptomatology: Systematic Review and Meta-Analysis. Am Acad Child

Adolesc Psychiatry 2011; 50: 991-1000

32.

Bisoglio J, Michaels T, Mervis J, Ashinoff B. Cognitive enhancement trough

action video game training: great expectations require greater evidence.

Frontier in Psychology 2014; 5: 136-140

33.

Biederman J, Faraone S. Attention-deficit hyperactivity disorder. Lancet

2005; 366:237-248.

34.

Newcorn J, Kratchvil C, Allen A et al. Atomoxetine and Osmotically

Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity

Disorder: Acute Comparison and Differential Response. Am J Psychiatry 2008;

165:721-730

35.

Daughton J, Kratochvil C. Review of ADHD Pharmacotherapies: Advantages,

Disadvantages, and Clinical Pearls. J Am Child Adolesc Psychiatry 2009: 48: 240-

248.

36.

Biederman J, Spencer T, Wilens T. Evidence -based pharmacotherapy

for attention- deficit hyperactivity disorder. International Journal of

Neuropsychopharmacology. 2004; 7:77-91

37.

Faraone S, Biderman J, Morley C, Spencer T. Effect of Stimulants on Height

and Weight: A Review of the Literature.

J.Am

Acad: Child Adolesc. Psychiatry.

2008; 47: 994-1009

38.

Cortese S, Holtmann M, Banaschewski et al. Practitioner Review: Current

best practice in the management of adverse events during treatment with

ADHD medications in children and adolescents. The J of Child Psychol and

Psychiatry 2013; 54:227-246

39.

Wilens T, Faraone S, Biederman J, Gunawardene S. Does Stimulant

Therapy of Attention-Deficit/Hyperactivity Disorder Beget Later. Pediatrics

2003;111;179

40.

Van den Ban E, Souverein P, Meijer W et al . Association between ADHD

drug use and injuries among children and adolescents . Eur Child Adolesc

Psychiatry 2014; 23:95-102

41.

Childress A, Berry S. Pharmacotherapy of Attention -Deficit Hyperactivity

Disorder in adolescents. Drug 2012; 72:309-325

42.

Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of

long term adherence to stimulant treatment in children with ADHD. J Am Acad

Child Adoles Psychiatry 2001; 40: 922-928

43.

Shaw M, Hodkings P, Caci H, Young S et al. A systematic review and

analysis of long term outcomes in attention deficit hyperactivity disorder:

effects of treatment and non-treatment. BMC medicine2012; 10:99-125

44.

Ilieva I, Farah M. Enhancement stimulants: perceived motivational and

cognitive advantages. Frontiers in Neuroscience 2013; 7: 198-204

[Trastorno por Déficit de Atención e Hiperactividad (TDAH) en adolescentes - Dra. Eliana Rodillo B.]